Stock Market News1 month Lilly’s Zepbound Receives FDA Approval for Sleep Apnea Zacks
FDA approves LLY’s obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.
XFDA approves LLY’s obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.
X